Cargando…
The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration
Tumor necrosis factor alpha (TNF-α) and its key role in modulating immune responses has been widely recognized as a therapeutic target for inflammatory and neurodegenerative diseases. Even though inhibition of TNF-α is beneficial for the treatment of certain inflammatory diseases, total neutralizati...
Autores principales: | Ortí-Casañ, Natalia, Boerema, Ate S., Köpke, Karina, Ebskamp, Amber, Keijser, Jan, Zhang, Yuequ, Chen, Tingting, Dolga, Amalia M., Broersen, Kerensa, Fischer, Roman, Pfizenmaier, Klaus, Kontermann, Roland E., Eisel, Ulrich L. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313728/ https://www.ncbi.nlm.nih.gov/pubmed/37391534 http://dx.doi.org/10.1038/s41598-023-36846-2 |
Ejemplares similares
-
The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation
por: Richter, Fabian, et al.
Publicado: (2021) -
Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS
por: Pegoretti, Valentina, et al.
Publicado: (2023) -
Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease
por: Ortí-Casañ, Natalia, et al.
Publicado: (2019) -
Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model
por: Dekens, Doortje W., et al.
Publicado: (2018) -
Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis
por: Fiedler, Timon, et al.
Publicado: (2023)